New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - brentuximab vedotin 50mg;  ;   - powder for injection - 50 mg - active: brentuximab vedotin 50mg     excipient: citric acid monohydrate polysorbate 80 sodium citrate dihydrate trehalose dihydrate - hodgkin lymphoma treatment of adult patients with cd30+ hodgkin lymphoma (hl) at higher risk of relapse or progression following asct. treatment of adult patients with relapsed or refractory cd30+ hl: 1. following autologous stem cell transplant (asct) or 2. following at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - vedolizumab 300mg;  ;   - powder for injection - 300 mg - active: vedolizumab 300mg     excipient: arginine hydrochloride histidine histidine hydrochloride monohydrate polysorbate 80 sucrose - treatment of adult patients with moderate to severe ulcerative colitis who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a tumour necrosis factor-alpha (tnf alpha) antagonist.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - lisdexamfetamine dimesilate 30mg;   - capsule - 30 mg - active: lisdexamfetamine dimesilate 30mg   excipient: croscarmellose sodium erythrosine gelatin magnesium stearate microcrystalline cellulose tekprint black sw-9008 titanium dioxide water - indicated for the treatment of attention deficit hyperactivity disorder (adhd) in adults, adolescents, and children aged 6 years and older. treatment should be commenced by a specialist. a diagnosis of adhd implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before 12 years of age.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - lisdexamfetamine dimesilate 50mg;   - capsule - 50 mg - active: lisdexamfetamine dimesilate 50mg   excipient: brilliant blue fcf croscarmellose sodium gelatin magnesium stearate microcrystalline cellulose tekprint black sw-9008 titanium dioxide water - indicated for the treatment of attention deficit hyperactivity disorder (adhd) in adults, adolescents, and children aged 6 years and older. treatment should be commenced by a specialist. a diagnosis of adhd implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before 12 years of age.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - lisdexamfetamine dimesilate 70mg;   - capsule - 70 mg - active: lisdexamfetamine dimesilate 70mg   excipient: brilliant blue fcf croscarmellose sodium erythrosine gelatin magnesium stearate microcrystalline cellulose tekprint black sw-9008 titanium dioxide water - indicated for the treatment of attention deficit hyperactivity disorder (adhd) in adults, adolescents, and children aged 6 years and older. treatment should be commenced by a specialist. a diagnosis of adhd implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before 12 years of age.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - octocog alfa 1000 [iu];   - injection with diluent - 1000 iu - active: octocog alfa 1000 [iu]   excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - octocog alfa 1500 [iu];   - injection with diluent - 1500 iu - active: octocog alfa 1500 [iu]   excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - octocog alfa 2000 [iu];   - injection with diluent - 2000 iu - active: octocog alfa 2000 [iu]   excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - octocog alfa 250 [iu];   - injection with diluent - 250 iu - active: octocog alfa 250 [iu]   excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - octocog alfa 3000 [iu];   - injection with diluent - 3000 iu - active: octocog alfa 3000 [iu]   excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.